Scientific Presentations

    Alheimer's Association International Conference 2026, held at London, UK during 12-15 July, 2026

  • 1) Masupirdine (A Pure 5-HT6 Antagonist): Updates from the Phase-3 Clinical Trial Program Targeting Agitation in Dementia of Alzheimer’s Type. View Presentation
  • 2) Usmarapride (SUVN-D4010), a Selective 5-HT4 Partial Agonist: An Update on the Clinical Development Program for the Treatment of Cognitive Disorders. View Presentation
  • 3) Evaluation of the Safety, Tolerability and Pharmacokinetics of Tenaclidine (SUVN-I6107), A M1 PAM in Healthy Subjects. View Presentation
  • 4) Efficacy and Safety of SUVN-N9503012, A Selective 5-HT1A Partial Agonist for the Symptomatic Treatment of Neurodegenerative Disorders. View Presentation
  • 5) SUVN-L1101142: A Muscarinic 4 Positive Allosteric Modulator for the Treatment of Alzheimer’s Disease and Schizophrenia. View Presentation

    AASM, American Academy of Sleep Medicine, SLEEP-2026 conference held at Baltimore, USA during 14-17, June 2026

  • 1) Samelisant (SUVN-G3031) Demonstrates Significant Reduction in Excessive Daytime Sleepiness In Patients with Narcolepsy: Phase-2 Results. View Presentation
  • 2) Phase-3 Clinical Development of Samelisant: Rationale and Study Design for Treating Excessive Daytime Sleepiness In Patients with Narcolepsy (AWAKE STUDY). View Presentation
  • 3) Study Design and Rationale for a Phase-2 Study of Samelisant (SUVN-G3031) for the Treatment of Cataplexy In Patients with Narcolepsy Type 1 View Presentation

    ASCP American Society of Clinical Psychopharmacology - 2026 held at Miami Beach, Florida, USA during 26-29th May, 2026

  • 1) Ropanicant (SUVN-911), anα4β2 nAChR Antagonist:A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, Evaluating the Efficacy and Safety of Ropanicant in Patients with Major Depressive Disorder. View Presentation
  • 2) Samelisant (SUVN-G3031): A Phase-3 Double-Blind, Randomized, Placebo-Controlled Study in Patients with Narcolepsy- Study Design View Presentation
  • 3) SUVN-L1101142, a Muscarinic M4 Positive Allosteric Modulator (M4 PAM) for the Treatment of Psychosis-Related Disorders and Conditions. View Presentation

    AAN-2026, American Academy of Neurology 2026 conference held at Chicago, USA during 18-22 Apr, 2026

  • 1) Masupirdine (A Pure 5-HT6 Receptor Antagonist): Clinical Development Program Targeting Agitation in Alzheimer’s Dementia – Phase-3 Study Updates View Presentation
  • 2) Preclinical Evaluation of Ropanicant, a Nicotinic Acetylcholine α4β2 Receptor Antagonist in Animal Models of Depression. View Presentation